Search

Author/Creator Coll, R.

1. 32 ACTIVATION OF REDOX-SENSITIVE INFLAMMASOMES UNDERLIES THE BIOLOGICAL PHENOTYPE OF MYELODYSPLASTIC SYNDROMES. (April 2015)

Authors:
Basiorka, A.; Mcgraw, K.; Eksioglu, E.; Chen, X.; Johnson, J.; Padron, E.; Komrokji, R.; Sokol, L.; Coll, R.; O'Neill, L.; Cooper, M.; Robertson, A.; Wei, S.; List, A.
Journal:
Leukemia research
Issue:
Volume 39(2015:Apr.) Supplement 1
Page Start:
S14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 90 INTENSIVE CHEMOTHERAPY VERSUS NO INTENSIVE TREATMENT IN HIGH RISK MYELODYSPLASTYC SYNDROME (MDS) NO-HSCT CANDIDATES. (April 2015)

Authors:
Bargay, J.; Xicoy, B.; Brunet, S.; Tormo, M.; Pedro, C.; Coll, R.; Talarn, C.; Marti, J.M.; Nomdedeu, M.; Font, X.; Sampol, A.; Borrás, J.; Valcárcel, D.; Ribera, J.M.; Sierra, J.
Journal:
Leukemia research
Issue:
Volume 39(2015:Apr.) Supplement 1
Page Start:
S46
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P1702: IMPACT OF CENTER CHARACTERISTICS AND MACROECONOMIC FACTORS ON THE OUTCOME OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC-INSPIRED PROTOCOLS. (23rd June 2022)

Authors:
Barba, P.; Morgades, M.; Montesinos, P.; Gonzalez Campos, J.; Torrent, A.; Gil, C.; Bernal, T.; Tormo, M.; Mercadal, S.; Saumell, S.; García-Cadenas, I.; Queipo de Llano, M.; Cervera, M.; Coll, R.; Bermudez, A.; Amigo, M.; Monsalvo, S.; Esteve, J.; Garcia Boyero, R.; Novo, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1583
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P385: DETECTION OF KMT2A PARTIAL TANDEM DUPLICATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS BY NGS. (23rd June 2022)

Authors:
Artigas-Baleri, A.; Oñate, G.; Brell, A.; Esteve, J.; Vives, S.; Tormo, M.; Arnan, M.; Garcia, A.; Coll, R.; Sampol, A.; Bargay, J.; Vall-llovera, F.; Salamero, O.; Nomdedéu, J.; Pratcorona, M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
285
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P565: IMPROVED OUTCOME OF PATIENS WITH ACUTE MYELOID LEUKEMIA HARBORING FLT3 MUTATION IN THE ERA OF TARGETED THERAPY. (23rd June 2022)

Authors:
Oñate, G.; Pratcorona, M.; Garrido, A.; Artigas, A.; Bataller, A.; Tormo, M.; Arnan, M.; Vives, S.; Coll, R.; Salamero, O.; Vall-Llovera, F.; Sampol, A.; Garcia, A.; Cervera, M.; Garcia Avila, S.; Bargay, J.; Ortin, X.; Esteve, J.; Sierra, J.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
464
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. P569: GILTERITINIB AND QUIZARTINIB IN RELAPSED/REFRACTORY (R/R) ACUTE MYELOBLASTIC LEUKEMIA (AML) WITH FLT3 MUTATIONS: A REAL-LIFE EFFECTIVENESS AND SAFETY STUDY. (23rd June 2022)

Authors:
Quintela, D.; Morgades, M.; Serrano, A.; Cervera, M.; Balerdi, A.; Díaz-Beyá, M.; Arnan, M.; Garrido, A.; Coll, R.; Tormo, M.; López-Marin, J.; Merchan, B.; Garcia, S.; Casado, M.; Sampol, A.; Esteve, J.; Martínez-Cuadrón, D.; Sierra, J.; Sanz, M. Á.; Ribera, J. M.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
468
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. P586: IADADEMSTAT COMBINATION WITH AZACITIDINE SHOWS ENCOURAGING SAFETY AND EFFICACY DATA IN ELDERLY AND UNFIT AML PATIENTS. (23rd June 2022)

Authors:
Salamero, O.; Somervaille, T.; Molero, A.; Acuña-Cruz, E.; Perez-Simon, J. A.; Coll, R.; Arnan Sangerman, M.; Merchan, B.; Perez, A.; Cano, I.; Rodriguez-Veiga, R.; Arevalo, M.; Gutierrez, S.; Buesa, C.; Bosch, F.; Montesinos, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
485
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Response to Azacitidine in a Series of 94 Patients with Chronic Myelomonocytic Leukemia from the Spanish Group of Myelodysplastic Syndromes. (April 2017)

Authors:
Triguero, A.; Xicoy, B.; Jiménez, M.J.; García, O.; Ramos, F.; Calabuig, M.; Liang, T.H.C.; Arzuaga, J.; Díaz-Beyá, M.; Medina, Á.; Bernal, T.; Brunet, S.; Coll, R.; Collado, R.; Borrás, J.; Talarn, C.; Sanz, G.
Journal:
Leukemia research
Issue:
Volume 55(2017)Supplement 1
Page Start:
S74
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria. (May 2022)

Authors:
Triguero, A.; Xicoy, B.; Zamora, L.; Jiménez, MJ.; García, O.; Calabuig, M.; Díaz-Beyá, M.; Arzuaga, J.; Ramos, F.; Medina, A.; Bernal, T.; Talarn, C.; Coll, R.; Collado, R.; Chen, T.Hua; Borrás, J.; Brunet, S.; Marchante, I.; Marco, V.; López-Cadenas, F.
Journal:
Leukemia research
Issue:
Volume 116(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗